Evaluation Of Infusion Reactions And Infusion Times In The N-Momentum Study Of Inebilizumab For NMOSD

被引：0
|
作者：
Tullman, Mark [1 ]
Ratchford, Jack [2 ]
She, Dewei [2 ]
Katz, Eliezer [2 ]
Cree, Bruce [3 ]
机构：
[1] MS Ctr Innovat Care, San Francisco, CA USA
[2] Viela Bio, Gaithersburg, MD USA
[3] UCSF, Multiple Sclerosis Ctr, San Francisco, CA USA
来源：
NEUROLOGY | 2021年 / 96卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1941
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Evaluation Of Infusion Reactions And Infusion Times In The N-Momentum Study Of Inebilizumab For NMOSD
    Tullman, M.
    Ratchford, J. N.
    She, D.
    Katz, E.
    Cree, B. A.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (1_SUPPL) : 80 - 81
  • [2] Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD
    Cree, Bruce A. C.
    Bennett, Jeffrey L.
    Kim, Ho Jin
    Weinshenker, Brian G.
    Pittock, Sean J.
    Wingerchuk, Dean
    Fujihara, Kazuo
    Paul, Friedemann
    Cutter, Gary R.
    Marignier, Romain
    Green, Ari J.
    Aktas, Orhan
    Hartung, Hans-Peter
    Williams, Ian M.
    Drappa, Jorn
    She, Dewei
    Cimbora, Daniel
    Rees, William
    Ratchford, John N.
    Katz, Eliezer
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (13) : 2052 - 2061
  • [3] Long Term Efficacy Outcomes with Inebilizumab Treatment in NMOSD: the N-MOmentum Trial
    Cree, Bruce
    Bennett, Jeffrey
    Weinshenker, Brian
    Wingerchuk, Dean
    Paul, Friedemann
    Kim, Ho Jin
    Pittock, Sean
    Fujihara, Kazuo
    Cutter, Gary
    Marignier, Romain
    Aktas, Orhan
    Hartung, Hans-Peter
    Green, Ari
    Drappa, Jorn
    She, Dewei
    Cimbora, Daniel
    Rees, William
    Ratchford, John
    Katz, Eliezer
    NEUROLOGY, 2021, 96 (15)
  • [4] Long Term Safety Outcomes with Inebilizumab Treatment in NMOSD: the N-MOmentum Trial
    Cree, Bruce
    Bennett, Jeffrey
    Weinshenker, Brian
    Wingerchuk, Dean
    Paul, Friedemann
    Kim, Ho Jin
    Pittock, Sean
    Fujihara, Kazuo
    Cutter, Gary
    Marignier, Romain
    Aktas, Orhan
    Hartung, Hans-Peter
    Green, Ari
    Drappa, Jorn
    She, Dewei
    Cimbora, Daniel
    Rees, William
    Ratchford, John
    Katz, Eliezer
    NEUROLOGY, 2021, 96 (15)
  • [5] Effect of Inebilizumab on Vaccine-Generated Antibody Titers in NMOSD Participants: Results from N-MOmentum study
    Hartung, H.
    Weinshenker, B.
    Pittock, S.
    Bennett, J. L.
    Smith, M.
    Mittereder, N.
    Rees, W. A.
    Cimbora, D.
    Patterson, K.
    Paul, F.
    Marignier, R.
    Wingerchuk, D.
    Cutter, G.
    Green, A.
    Fujihara, K.
    Kim, H.
    Levy, M.
    Aktas, O.
    Cree, B.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 165 - 165
  • [6] Safety and Efficacy of Inebilizumab in AQP4+NMOSD Participants with History of Immunosuppression Treatment Prior to N-MOmentum Study
    Paul, Friedemann
    Marignier, Roman
    Lindsey, John
    Kim, Ho Jin
    She, Dewei
    Cimbora, Daniel
    Patterson, Kristina
    Cree, Bruce
    NEUROLOGY, 2023, 100 (17)
  • [7] Safety and Efficacy of Inebilizumab in AQP4+NMOSD Participants with history of Immunosuppression Treatment prior to N-MOmentum Study
    Kim, Ho Jin
    Patterson, Kristina
    Paul, Friedemann
    Marignier, Romain
    Lindsey, J. W.
    She, Dewei
    Dinh, Quinn
    Cimbora, Dan
    Cree, Bruce A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (07) : NP8 - NP9
  • [8] Safety and efficacy of Inebilizumab in AQP4+NMOSD participants with history of immunosuppression treatment prior to N-MOmentum study
    Paul, F.
    Marignier, R.
    Lindsey, J. W.
    Kim, H. J.
    She, D.
    Cimbora, D.
    Patterson, K. R.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 422 - 423
  • [9] Safety and efficacy of inebilizumab in NMOSD over a mean treatment duration of 3.2 years: end of study data from the N-MOmentum trial
    Cree, B. A. C.
    Bennett, J. L.
    Weinshenker, B. G.
    Wingerchuk, D. M.
    Paul, F.
    Kim, H. -J.
    Pittock, S. J.
    Fujihara, K.
    Cutter, G. R.
    Marignier, R.
    Aktas, O.
    Hartung, H. -P.
    Green, A. J.
    Drappa, J.
    She, D.
    Cimbora, D.
    Rees, W. A.
    Smith, M.
    Ratchford, J. N.
    Katz, E.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 158 - 160
  • [10] Efficacy of inebilizumab in the European Union subpopulation of the N-MOmentum trial
    Paul, F.
    Aktas, O.
    Marignier, R.
    Boegl, K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 474 - 474
12345